PAB Establishes Clinical Advisory Committee
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The committee includes experts from Australia, the United States, and Europe, who will provide guidance on clinical trial design and implementation. The committee aims to enhance Patrys's engagement with the international clinical community and ensure robust trial designs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Patrys
- Appendix 4E - Preliminary Final Report
- Ethics Approval Secured for Phase 1A Clinical Trial
- Investor Presentation - TechKnow Invest Roadshow
- Appendix 4C - Quarterly - 30 June 2026
- Patrys Secures 50% Revenue Share in IP Commercialisation
Later from Patrys
- First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
- Appendix 4G and Corporate Governance Statement
- Annual Report - 30 June 2025
- Appendix 4E Variance Report
- Patrys Completes Cohort 1 Dosing and Follow-Up
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys